lumasiran (Oxlumo)

Indications

• treatment of primary hyperoxaluria type 1

Dosage

• 0.5 mL lumasiran 189 mg/mL injection

Adverse effects

• injection site reactions
• abdominal pain

Mechanism of action

• double-stranded small interfering ribonucleic acid (siRNA)
• reduces levels of glycolate oxidase by targeting HAO1 mRNA in hepatocytes through RNA interference

More general terms

• short interfering double-stranded RNA; antisense oligonucleotide (siRNA, microRNA, miRNA)
• metabolic agent (metabolic modifier)